- Home
- AIRS vs ABEO Comparison
AIRS vs ABEO Comparison
Compare AIRS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ABEO
- Stock Information
- Founded
- AIRS 2012
- ABEO N/A
- Country
- AIRS United States
- ABEO United States
- Employees
- AIRS N/A
- ABEO N/A
- Industry
- AIRS Medical/Nursing Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ABEO Health Care
- Exchange
- AIRS Nasdaq
- ABEO Nasdaq
- Market Cap
- AIRS 249.9M
- ABEO 243.9M
- IPO Year
- AIRS 2021
- ABEO 1980
- Fundamental
- Price
- AIRS $4.79
- ABEO $6.38
- Analyst Decision
- AIRS Hold
- ABEO Strong Buy
- Analyst Count
- AIRS 2
- ABEO 3
- Target Price
- AIRS $5.50
- ABEO $18.00
- AVG Volume (30 Days)
- AIRS 108.2K
- ABEO 245.9K
- Earning Date
- AIRS 11-07-2024
- ABEO 11-11-2024
- Dividend Yield
- AIRS N/A
- ABEO N/A
- EPS Growth
- AIRS N/A
- ABEO N/A
- EPS
- AIRS N/A
- ABEO N/A
- Revenue
- AIRS $193,025,000.00
- ABEO N/A
- Revenue This Year
- AIRS N/A
- ABEO N/A
- Revenue Next Year
- AIRS $11.85
- ABEO $7,097.06
- P/E Ratio
- AIRS N/A
- ABEO N/A
- Revenue Growth
- AIRS 6.58
- ABEO 147.52
- 52 Week Low
- AIRS $2.92
- ABEO $3.05
- 52 Week High
- AIRS $8.30
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- AIRS 51.97
- ABEO 65.86
- Support Level
- AIRS $4.36
- ABEO $6.06
- Resistance Level
- AIRS $5.95
- ABEO $6.48
- Average True Range (ATR)
- AIRS 0.52
- ABEO 0.34
- MACD
- AIRS -0.01
- ABEO 0.05
- Stochastic Oscillator
- AIRS 40.33
- ABEO 91.38
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.